酶抑制是寻找用于预防和治疗许多健康问题的新诊断设施的最常用方法之一。酪氨酸酶和胰脂肪酶抑制剂已分别用于治疗皮肤色素沉着问题和肥胖症。本研究主要侧重于评价新合成的磺酸盐衍生物(3a - 3i)对酪氨酸酶和胰脂肪酶的酶抑制作用。2-(((5-甲基苯并[ d ]噻唑-2-基)亚氨基)甲基)苯基磺酸盐衍生物的结构表征通过1 H NMR、13 C NMR和HR-MS分析进行。根据体外酶抑制方法,化合物3e具有最高的酪氨酸酶抑制活性(46.9 ± 3.6 µM IC 50值)。另一方面,化合物3f、3e和3g的有效胰脂肪酶抑制活性分别由它们的低IC 50值58.3±6.7μM、59.5±13.8μM和64.8±6.3μM确定。还分别对合成的化合物与酪氨酸酶和胰脂肪酶进行了分子对接研究。最后,进行 ADME 研究以确定目标化合物的药代动力学、药物相似性和药用特性。
Ruthenium(II) complexes of mixed ligands (benzothiazolyl Schiff base, PPh3, and AsPh3) have been synthesized. Structural features of the ligands and complexes were determined by various physico-chemical and spectral techniques. In order to ascertain the potential of the above-synthesized compounds towards biomolecular interactions, titration experiments involving interaction with calf thymus DNA (CT-DNA)
Cyclocondensation of salicylaldehydes with alkyl acetoacetates and 2-aminobenzothiazoles or 2-amino-5-methylthiazole under classical Biginellireaction conditions gives rare hetarylamino substituted 2,2′-spirobischromanecarboxylate derivatives. The mechanism and observed stereoselectivity of the unexpected pseudo-four-component process are discussed.